Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.5 SEK | +0.18% | -5.17% | +15.06% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.06% | 710M | - | ||
+73.17% | 12.38B | B- | ||
-18.74% | 7.92B | C+ | ||
+16.15% | 7.2B | C- | ||
+4.81% | 5.84B | B | ||
+5.99% | 5.07B | D+ | ||
+27.07% | 4.53B | - | ||
-21.67% | 3.88B | B- | ||
-40.82% | 2.23B | C | ||
+1.49% | 2.02B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- IMP A SDB Stock
- Ratings Implantica AG